|
1
|
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
|
N Engl J Med
|
2009
|
4.59
|
|
2
|
Clinical guide to ABO-incompatible allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
2.17
|
|
3
|
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.
|
Transfusion
|
2003
|
2.05
|
|
4
|
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
|
Biol Blood Marrow Transplant
|
2008
|
1.83
|
|
5
|
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?
|
Cytotherapy
|
2009
|
1.73
|
|
6
|
Hemochromatosis subjects as allogeneic blood donors: a prospective study.
|
Transfusion
|
2003
|
1.45
|
|
7
|
The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
1.42
|
|
8
|
Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.
|
Biol Blood Marrow Transplant
|
2008
|
1.41
|
|
9
|
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
|
Blood
|
2008
|
1.28
|
|
10
|
Oxidative stress in asymptomatic subjects with hereditary hemochromatosis.
|
Am J Hematol
|
2007
|
1.08
|
|
11
|
Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis.
|
Am J Cardiol
|
2006
|
1.04
|
|
12
|
Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis?
|
Echocardiography
|
2009
|
0.95
|
|
13
|
Massive transfusion and nonsurgical hemostatic agents.
|
Crit Care Med
|
2008
|
0.88
|
|
14
|
Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis.
|
Am J Cardiol
|
2006
|
0.88
|
|
15
|
Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity.
|
Am J Cardiol
|
2011
|
0.88
|
|
16
|
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
|
J Immunol
|
2013
|
0.86
|
|
17
|
Exercise capacity of cardiac asymptomatic hereditary hemochromatosis subjects.
|
Med Sci Sports Exerc
|
2007
|
0.84
|
|
18
|
Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation.
|
Transfusion
|
2006
|
0.80
|
|
19
|
Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors.
|
Blood
|
2002
|
0.79
|
|
20
|
Placebo-controlled study of intravenous magnesium supplementation during large-volume leukapheresis in healthy allogeneic donors.
|
Transfusion
|
2005
|
0.77
|
|
21
|
Changes in exercise capacity in subjects with cardiac asymptomatic hereditary hemochromatosis during a follow-up after 5 yrs.
|
Am J Phys Med Rehabil
|
2012
|
0.76
|
|
22
|
Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma.
|
Transfusion
|
2004
|
0.75
|
|
23
|
Changes in left ventricular diastolic function of asymptomatic hereditary hemochromatosis subjects during five years of follow-up.
|
Am J Cardiol
|
2011
|
0.75
|
|
24
|
Heart rate recovery is lower following supine exercise in asymptomatic hereditary hemochromatosis subjects compared with healthy controls.
|
J Cardiopulm Rehabil Prev
|
2007
|
0.75
|